The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Patterns of progression in bone and soft tissue following treatment with Ra-223 in metastatic castrate resistant prostate cancer (mCRPC).
 
Megan Ann McNamara
Honoraria - Exelixis
Research Funding - Agensys (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Janssen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Agensys; Clovis Oncology
 
Michala Ritz
No Relationships to Disclose
 
Bennett Chin
No Relationships to Disclose
 
Jorge Oldan
Honoraria - Wolters Kluwer
 
Aseem Anand
Consulting or Advisory Role - EXINI Diagnostics
Travel, Accommodations, Expenses - EXINI Diagnostics
 
Taofik Oyekunle
No Relationships to Disclose
 
Monika Anand
No Relationships to Disclose
 
Andrew J. Armstrong
Honoraria - Dendreon; Janssen Oncology; Sanofi
Consulting or Advisory Role - Bayer; Dendreon; Janssen Biotech; Medivation; Novartis; Pfizer; Sanofi
Speakers' Bureau - Dendreon; Sanofi
Research Funding - Active Biotech (Inst); Astellas Pharma (Inst); Bayer (Inst); Dendreon (Inst); Gilead Sciences (Inst); Janssen Oncology (Inst); Medivation (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Circulating tumor cell novel capture technology (Inst)
Travel, Accommodations, Expenses - Dendreon; Janssen Biotech; Medivation; Sanofi
 
Daniel J. George
Honoraria - Bayer; BIOPHARM; Dendreon; Medivation; Novartis; Sanofi
Consulting or Advisory Role - Acceleron Pharma; Astellas Pharma; Bayer; Bristol-Myers Squibb; Celgene; Dendreon; Exelixis; Genentech; GlaxoSmithKline; Innocrin Pharma; Janssen; Medivation; Merck Sharp & Dohme; Myovant Sciences; Novartis; Pfizer; Sanofi
Speakers' Bureau - Bayer; Dendreon; Novartis; Sanofi
Research Funding - Acerta Pharma (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Dendreon (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Janssen Oncology (Inst); Millennium (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Viamet Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Bayer; Exelixis; Genentech/Roche; Medivation; Merck; Pfizer